SLAMF6
SLAM family member 6
Also known as: CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000, SLAF6_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96DU3
- Gene
- SLAMF6
- Ensembl
- ENSG00000162739
- Chromosome
- 1
- Canonical length
- 332 aa
- Protein class
- CD markers, Predicted membrane proteins
- Subcellular location
- Plasma membrane,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene is a type I transmembrane protein, belonging to the CD2 subfamily of the immunoglobulin superfamily. This encoded protein is expressed on Natural killer (NK), T, and B lymphocytes. It undergoes tyrosine phosphorylation and associates with the Src homology 2 domain-containing protein (SH2D1A) as well as with SH2 domain-containing phosphatases (SHPs). It functions as a coreceptor in the process of NK cell activation. It can also mediate inhibitory signals in NK cells from X-linked lymphoproliferative patients. Alternative splicing results in multiple transcript variants encoding distinct isoforms.[provided by RefSeq, May 2010]
Canonical amino-acid sequenceUniProt
332 residues, UniProt reviewed canonical sequence.
>Q96DU3|SLAMF6
1 MLWLFQSLLF VFCFGPGNVV SQSSLTPLMV NGILGESVTL PLEFPAGEKV NFITWLFNET
61 SLAFIVPHET KSPEIHVTNP KQGKRLNFTQ SYSLQLSNLK MEDTGSYRAQ ISTKTSAKLS
121 SYTLRILRQL RNIQVTNHSQ LFQNMTCELH LTCSVEDADD NVSFRWEALG NTLSSQPNLT
181 VSWDPRISSE QDYTCIAENA VSNLSFSVSA QKLCEDVKIQ YTDTKMILFM VSGICIVFGF
241 IILLLLVLRK RRDSLSLSTQ RTQGPAESAR NLEYVSVSPT NNTVYASVTH SNRETEIWTP
301 RENDTITIYS TINHSKESKP TFSRATALDN VVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SLAMF6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.45
- Highest tissue expression
- 58 nTPM
Expression across tissuesHPA
Tissue
- lymph node: 58 nTPM
- tonsil: 46 nTPM
- spleen: 31 nTPM
- appendix: 20 nTPM
- thymus: 18 nTPM
- small intestine: 13 nTPM
Single-cell type
- t-cells: 136 nCPM
- nk-cells: 110 nCPM
- b-cells: 63 nCPM
- innate lymphoid cells: 38 nCPM
- late spermatids: 29 nCPM
- plasma cells: 20 nCPM
Immune cell
- memory CD8 T-cell: 71 nTPM
- gdT-cell: 56 nTPM
- T-reg: 46 nTPM
- NK-cell: 42 nTPM
- naive CD8 T-cell: 40 nTPM
- MAIT T-cell: 39 nTPM
Brain region
- cerebellum: 3.6 nTPM
- cerebral cortex: 2.7 nTPM
- medulla oblongata: 2.7 nTPM
- thalamus: 2.7 nTPM
- choroid plexus: 2.6 nTPM
- pons: 2.5 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.68
- gnomAD pLI
- 0.02
- gnomAD missense Z
- 0.57
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- immune response
- innate immune response
- positive regulation of interleukin-17 production
- positive regulation of natural killer cell mediated cytotoxicity
- positive regulation of type II interferon production
- T cell activation
- T-helper 17 cell lineage commitment
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SLAMF6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
- PTN6
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SLAMF6 as an antibody target. Whether an autoantibody or antibody against SLAMF6 could matter depends on whether native SLAMF6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SLAMF6 is annotated at the cell surface, where native SLAMF6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SLAMF6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...